Atlas Trials

Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

Clinical trial NCT00169169 · TERMINATED

Trial details

NCT number
NCT00169169
Sponsor
Lymphoma Study Association
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
CD20-Positive Large B-Cell Lymphoma
Start date
1999-10-01
Enrollment
430

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.